Potential control of multiple sclerosis by cannabis and the endocannabinoid system

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 5, 2012, Pages 624-641

  Pryce, Gareth ^a   Baker, David ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cannabis; Endocannabinoid; Experimental allergic encephalomyelitis; Multiple sclerosis; Neuroprotection; Spasticity

Indexed keywords

2 ARACHIDONOYL GLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AMINO ACID TRANSPORTER; ANANDAMIDE; ARVANIL; BACLOFEN; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABIS; CYCLIC AMP; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; GPR18 RECEPTOR; GPR55 RECEPTOR; KAINIC ACID; N (3 FURYLMETHYL)ARACHIDONAMIDE; NABIXIMOLS; PERTUSSIS TOXIN; RENZODIAZEPINE; TIZANIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BORDETELLA PARAPERTUSSIS; CELL ACTIVATION; CYTOKINE PRODUCTION; DISEASE CONTROL; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; EXCITOTOXICITY; EXPERIMENTAL AUTOIMMUNE UVEORETINITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; IMMUNOMODULATION; IMMUNOTHERAPY; LIMB SPASTICITY; MICROGLIA; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SMOKING; SPASTICITY; TRANSGENIC ANIMAL; TREATMENT INDICATION; TREMOR; URINE INCONTINENCE; UVEORETINITIS; WASTING SYNDROME;

EID: 84863917450     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712801661310     Document Type: Review

References (215)

1. Devane, W.A.; Dysarz, F.A.; Johnson, M.R.; Melvin, L.S.; Howlett, A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 1988, 34(5), 605-613.
2. Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346(6284), 561-564.
3. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365(6441), 61-65.
4. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258(5090), 1946-1949.
5. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N.E.; Schatz, A.R.; Gopher, A.; Almog, S.; Martin, B.R.; Compton, D.R.; Pertwee, R.G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 1995, 50(1), 83-90.
6. Stella, N.; Schweitzer, P.; Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature, 1997, 388(6644), 773-778.
7. Baker, D.; Pryce, G.; Davies, W.L.; Hiley C.R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci., 2006, 27(1), 1-4.
8. Ryberg, E.; Larsson, N.; Sjögren, S.; Hjorth, S.; Hermansson, N.O.; Leonova, J.;Elebring, T.; Nilsson, K.; Drmota, T; Greasley, P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152(7), 1092-1101.
9. McHugh, D.; Hu, S.S.; Rimmerman, N.; Juknat, A.; Vogel, Z.; Walker, J.M.; Bradshaw, H.B. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci., 2010, 11, 44.
10. Zygmunt, P.M.; Petersson, J.; Andersson, D.A.; Chuang, H.; Sorgard, M.; Di Marzo, V.; Julius, D.; Hogestatt, E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 1999, 400(6743), 452-457.
11. McAllister, S.D.; Tao, Q.; Barnett-Norris, J.; Buehner, K.; Hurst, D.P.; Guarnieri, F.; Reggio, P.H.; Nowell Harmon, K.W.; Cabral, G.A.; Abood, M.E. A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. Biochem. Pharmacol., 2002, 63(12), 2121-2136.
12. Howlett, A.C.; Barth, F.; Bonner, T.I.; Cabral, G.; Casellas, P.; Devane, W.A.; Felder, C.C.; Herkenham, M.; Mackie, K.; Martin, B.R.; Mechoulam, R; Pertwee, R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 2002, 54(2), 161-202.
13. Moldrich, G.; Wenger, T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides, 2000, 21(11), 1735-1742.
14. Herkenham, M.; Lynn, A.B.; Johnson, M.R.; Melvin, L.S.; de Costa, B.R.; Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci., 1991, 11(2), 563-583.
15. Howlett, A.C. Inhibition of neuroblastoma adenylate cyclase by cannabinoid and nantradol compounds. Life Sci., 1984, 35(17), 1803-1810.
16. Bonhaus, D.W.; Chang, L.K.; Kwan, J.; Martin, G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther., 1998, 287(3), 884-888.
17. Breivogel, C.S.; Sim, L.J.; Childers, S.R. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther., 1997, 282(3), 1632-1642.
18. Howlett, A.C.; Breivogel, C.S.; Childers, S.R.; Deadwyler, S.A.; Hampson, R.E.; Porrino, L.J. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology, 2004, 47(Suppl 1), 345-358.
19. Wilson, R.I.; Nicoll, R.A. Endocannabinoid signalling in the brain. Science, 2002, 296, 678-668.
20. Gebremedhin, D.; Lange, A.R.; Campbell, W.B.; Hillard, C.J.; Harder, D.R. Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current. Am. J. Physiol., 1999, 276(6 Pt2), H2085-H2093.
21. Chemin, J.; Monteil, A.; Perez-Reyes, E.; Nargeot, J.; Lory, P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. Embo J., 2001, 20(24), 7033-7040.
22. Mackie, K.; Lai, Y.; Westenbroek, R.; Mitchell, R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci., 1995, 15(10), 6552-6561.
23. Garcia, D.E.; Brown, S.; Hille, B; Mackie, K. Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J. Neurosci., 1998, 18(8), 2834-2841.
24. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 1995, 232(1), 54-61.
25. Klein, T.W.;Newton, C.; Larsen, K.; Lu, L.; Perkins, I.; Nong, L.; Friedman, H. The cannabinoid system and immune modulation. J. Leukoc. Biol., 2003, 74(4), 486-496.
26. Bouaboula, M.; Rinaldi, M.; Carayon, P.; Carillon, C.; Delpech, B.; Shire, D.; Le Fur, G.; Casellas, P. Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 1993, 214(1), 173-180.
27. Börner, C.; Hollt, V.; Sebald, W.; Kraus, J. Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. J. Leukoc. Biol., 2007, 81(1), 336-343.
28. Freund, T.F.; Katona, I.; Piomelli, D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev., 2003, 83(3), 1017-1066.
29. Kreitzer, A.C.; Carter, A.G.; Regehr, W.G. Inhibition of interneuron firing extends the spread of endocannabinoid signaling in the cerebellum. Neuron, 2002, 34(5), 787-796.
30. Gao, Y.; Vasilyev, D.V.; Goncalves, M.B.; Howell, F.V.; Hobbs, C.; Reisenberg, M.; Shen, R.; Zhang, M.Y.; Strassle, B.W.; Lu, P.; Mark, L.; Piesla, M.J.; Deng, K.; Kouranova, E. V;, Ring, R.H.; Whiteside, G.T.; Bates, B.; Walsh, F.S.; Williams, G.; Pangalos, M. N,; Samad, T.A.; Doherty, P. Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J. Neurosci., 2010, 30(6), 2017-2024.
31. Tanimura, A.; Yamazaki, M.; Hashimotodani, Y.; Uchigashima, M.; Kawata, S.; Abe, M.; Kita, Y.; Hashimoto, K.; Shimizu, T.; Watanabe, M.; Sakimura, K.; Kano, M. The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron, 2010, 65(3), 320-327.
32. Fimiani, C.;Liberty, T.; Aquirre, A.J.; Amin, I.; Ali, N.; Stefano, G.B. Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Prostaglandins Other Lipid Mediat., 1999, 57(1), 23-34.
33. Makara, J.K.; Katona, I.; Nyiri, G.; Nemeth, B.; Ledent, C.; Watanabe, M.; de Vente, J.; Freund, T.F.; Hajos, N. Involvement of nitric oxide in depolarization-induced suppression of inhibition in hippocampal pyramidal cells during activation of cholinergic receptors. J. Neurosci., 2007, 27(38), 10211-10222.
34. Cabral, G.A.; Harmon, K.N.; Carlisle, S.J. Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. Adv. Exp. Med. Biol., 2001, 493, 207-214.
35. Maresz, K.; Carrier, E.J.; Ponomarev, E.D.; Hillard, C.J.; Dittel, B.N. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J. Neurochem., 2005, 95(2), 437-445.
36. Ashton, J.C.; Rahman, R.M.;Nair, S.M.; Sutherland, B.A.; Glass, M.; Appleton, I. Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci. Lett., 2007, 412(2), 114-117.
37. Xu, H.; Cheng, C.L.; Chen, M.; Manivannan, A.; Cabay, L.; Pertwee, R.G.; Coutts, A.; Forrester, J.V. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J. Leukoc. Biol., 2007, 82(3), 532-541.
38. Buckley, N.E. The peripheral cannabinoid receptor knockout mice: an update. Br. J. Pharmacol., 2008, 153(2), 309-318.
39. Bayewitch, M.; Avidor-Reiss, T.; Levy, R.; Barg, J.; Mechoulam, R.; Vogel, Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett., 1995, 375(1-2), 143-147.
40. Bouaboula, M.; Poinot-Chazel, C.; Marchand, J.; Canat, X.; Bourrie, B,; Rinaldi-Carmona, M.; Calandra, B.; Le Fur, G.; Casellas, P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogenactivated protein kinase and induction of Krox-24 expression. Eur. J. Biochem., 1996, 237(3), 704-711.
41. Felder, C.C.; Joyce, K.E.; Briley, E.M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A.L.;Mitchell, R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol., 1995, 48(3), 443-450.
42. Glass, M.; Felder, C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci., 1997, 17(14), 5327-5333.
43. Walter, L.; Franklin, A.; Witting, A.; Wade, C.; Xie, Y.; Kunos, G.; Mackie, K.; Stella, N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci., 2003, 23(4), 1398-1405.
44. Oka, S.; Nakajima, K.; Yamashita, A.; Kishimoto, S.; Sugiura, T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun., 2007, 362(4), 928-934.
45. Kapur, A.; Zhao, P.; Sharir, H.; Bai, Y.; Caron, M.G.; Barak, L.S.; Abood, M.E. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem., 2009, 284(43), 29817-29827.
46. Lauckner, J.E.; Jensen, J. B; Chen, H.Y.; Lu, H.C.; Hille, B.;Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. USA, 2008, 105(7), 2699-2704.
47. Bondarenko, A.; Waldeck-Weiermair, M.; Naghdi. S.; Poteser, M.; Malli, R.; Graier, W.F. GPR55-dependent and-independent ion signalling in response to lysophosphatidylinositol in endothelial cells. Br. J. Pharmacol., 2010, 161(2), 308-320.
48. Zhang, X.; Maor, Y.; Wang, J.F.; Kunos, G.; Groopman, J.E. Endocannabinoid-like N-arachidonoyl serine is a novel proangiogenic mediator. Br. J. Pharmacol., 2010, 160(7), 1583-1594.
49. Whyte, L.S.; Ryberg, E.; Sims, N.A.; Ridge, S.A.; Mackie, K.; Greasley, P.J.; Ross, R, A; Rogers, M.J. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. USA, 2009, 106(38), 16511-16516.
50. Staton, P.C.; Hatcher, J.P.; Walker, D.J.; Morrison, A.D.; Shapland, E, M.; Hughes, J, P.; Chong, E.; Mander, P.K.; Green, P.J.; Billinton, A.; Fulleylove, M.; Lancaster, H, C.; Smith, J.C.; Bailey, L.T.;Wise, A.; Brown, A.J.; Richardson, J.C.; Chessell, I.P. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain, 2008, 139(1), 225-236.
51. De Petrocellis, L.; Bisogno, T.; Maccarrone, M.; Davis, J.B.; Finazzi-Agro, A.; Di Marzo, V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem., 2001, 276(16), 12856-12863.
52. Nemeth, J.; Helyes, Z.; Than, M.; Jakab, B.; Pinter, E.; Szolcsanyi, J. Concentration-dependent dual effect of anandamide on sensory neuropeptide release from isolated rat tracheae. Neurosci. Lett., 2003, 336(2), 89-92.
53. Wise, L.E.; Shelton, C.C.; Cravatt, B.F.; Martin, B.R.; Lichtman, A.H. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors. Eur. J. Pharmacol., 2007, 557(1), 44-48.
54. Dinis, P.; Charrua, A.; Avelino, A.; Yaqoob, M.; Bevan, S.; Nagy, I.; Cruz, F. Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J. Neurosci., 2004, 24(50), 11253-11263.
55. Singh Tahim, A.; Santha, P.; Nagy, I. Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons. Neuroscience, 2005, 136(2), 539-548.
56. Samuelson, L.C.; Swanberg, L.J.; Gantz, I. Mapping of the novel G protein-coupled receptor Gpr18 to distal mouse chromosome 14. Mamm. Genome, 1996, 7(12), 920-921.
57. Gantz, I.; Muraoka, A.; Yang, Y.K.; Samuelson, L.C.; Zimmerman, E.M.; Cook, H.; Yamada, T. Cloning and chromosomal localization of a gene (GPR18) encoding a novel seven transmembrane receptor highly expressed in spleen and testis. Genomics, 1997, 42(3), 462-466.
58. Kohno, M.; Hasegawa, H.; Inoue, A.; Muraoka, M.; Miyazaki, T.; Oka, K.; Yasukawa, M. Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem. Biophys. Res. Commun., 2006, 347(3), 827-832.
59. Járai, Z.; Wagner, J.A.; Varga, K.; Lake, K.D.; Compton, D.R.; Martin, B.R.; Zimmer, A.M.; Bonner, T.I.; Buckley, N.E.; Mezey, E.; Razdan, R.K.; Zimmer, A.; Kunos, G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA, 1999, 96(24), 14136-14141.
60. Pertwee, R.G. In: Pharmacological Actions of Cannabinoids; Pertwee, R.G., Ed.; Springer-Verlag, Heidelberg, Germany, 2005, pp. 1-51.
61. Sugiura, T; Waku, K. 2-Arachidonoylglycerol and the cannabinoid receptors. Chem. Phys. Lipids, 2000, 108(1-2), 89-106.
62. Sugiura, T.; Kobayashi, Y.;Oka, S; Waku, K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot. Essent. Fatty Acid, 2002, 66(2-3), 173-192.
63. Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D.E.; Kustanovich, I.; Mechoulam, R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA, 2001, 98(7), 3662-3665.
64. Porter, A.C.; Sauer, J.M.; Knierman, M.D.; Becker, G.W.; Berna, M.J.; Bao, J.; Nomikos, G.G.;Carter, P.; Bymaster, F.P.; Leese, A. B; Felder, C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 2002, 301(3), 1020-1024.
65. Bisogno, T.; Melck, D.; Bobrov, M.; Gretskaya, N.M.; Bezuglov, V.V.; De Petrocellis, L.; Di Marzo, V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J., 2000, 351(3), 817-824.
66. Burstein, S.H.; Rossetti, R.G.; Yagen, B.; Zurier, R.B. Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat., 2000, 61(1-2), 29-41.
67. Huang, S.M.; Bisogno, T.; Petros, T.J.; Chang, S.Y.; Zavitsanos, P.A.; Zipkin, R.E.; Sivakumar, R.; Coop, A.; Maeda, D.Y.; De Petrocellis, L.; Burstein, S.; Di Marzo, V.; Walker J.M. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem., 2001, 276(46), 42639-42644.
68. Okamoto, Y.; Morishita, J.; Tsuboi, K.; Tonai, T.; Ueda, N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem., 2004, 279(7), 5298-5305.
69. Leung, D.; Saghatelian, A.; Simon, G.M.; Cravatt, B.F. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry, 2006, 45(15), 4720-4726.
70. Di Marzo, V. Endocannabinoids: synthesis and degradation. Rev. Physiol. Biochem. Pharmacol., 2008, 160, 1-24.
71. Wang, J; Ueda, N. Biology of endocannabinoid synthesis system. Prostaglandins Other Lipid Mediat., 2009, 89(3-4), 112-119.
72. Bisogno, T.; Howell, F.; Williams, G.; Minassi, A.; Cascio, M.G.; Ligresti, A.; Matias, I.; Schiano-Moriello, A.; Paul, P.; Williams, E.J.; Gangadharan, U.; Hobbs, C.; Di Marzo, V.; Doherty, P. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol., 2003, 163(3), 463-468.
73. Basavarajappa, B.S. Critical enzymes involved in endocannabinoid metabolism. Protein Pept. Lett., 2007, 14(3), 237-246.
74. Jung, K.M.; Astarita, G.; Zhu, C.; Wallace, M.; Mackie, K.; Piomelli, D. A key role for diacylglycerol lipase-alpha in metabotropic glutamate receptor-dependent endocannabinoid mobilization. Mol. Pharmacol., 2007, 72(3), 612-621.
75. Beltramo, M.; Stella, N.; Calignano, A.; Lin, S.Y.; Makriyannis, A.; Piomelli, D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 1997, 277(5329), 1094-1097.
76. Baker, D.; Pryce, G.; Croxford, J.L.; Brown, P.; Pertwee, R.G.; Makriyannis, A.; Khanolkar, A.; Layward, L.; Fezza, F.; Bisogno, T.; Di Marzo, V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J., 2001, 15(2), 300-302.
77. de Lago, E.; Ligresti, A.; Ortar, G.; Morera, E.; Cabranes, A.; Pryce, G.; Bifulco, M.; Baker, D.; Fernandez-Ruiz, J. Di Marzo, V. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur. J. Pharmacol., 2004, 484(2-3), 249-257.
78. de Lago, E.; Fernández-Ruiz, J.; Ortega-Gutiérrez, S.; Cabranes, A.; Pryce, G.; Baker, D.; López-Rodríguez, M.; Ramos, J.A. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur. Neuropsychopharmacol., 2006, 16(1), 7-18.
79. Ligresti, A.; Cascio, M.G.; Pryce, G.; Kulasegram, S.; Beletskaya, I.; De Petrocellis, L.; Saha, B.; Mahadevan, A.; Visintin, C.; Wiley, J.L.; Baker, D.; Martin, B.R.; Razdan, R.K.; Di Marzo, V. New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br. J. Pharmacol., 2006, 147(1), 83-91.
80. Glaser, S.T.; Abumrad, N.A.; Fatade, F.; Kaczocha, M.; Studholme, K.M.; Deutsch, D.G. Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. USA, 2003, 100(7), 4269-4274.
81. Jarrahian; A., Manna, S.; Edgemond, W.S.; Campbell, W. B; Hillard, C.J. Structure-activity relationships among Narachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. J. Neurochem., 2000, 74(6), 2597-2606.
82. Ralevic, V.; Kendall, D.A.; Jerman, J.C.; Middlemiss, D.N.; Smart, D. Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur. J. Pharmacol., 2001, 424(3), 211-219.
83. Brooks, J.W.; Pryce, G.; Bisogno, T.; Jagger, S.I.; Hankey, D.J.R.; Brown, P.; Bridges, D.; Ledent, C.; Bifulco, M.; Rice, A.S.; Di Marzo, V.; Baker, D. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. Eur. J. Pharmacol., 2002, 439(1-3), 83-92.
84. De Petrocellis, L.; Bisogno, T.; Davis, J.B.; Pertwee, R.G.; Di Marzo, V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett., 2000, 483(1), 52-56.
85. Lopez-Rodriguez, M.L.; Viso, A.; Ortega-Gutierrez, S.; Lastres-Becker, I.; Gonzalez, S.; Fernandez-Ruiz, J.; Ramos, J.A. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J. Med. Chem., 2001, 44(26), 4505-4508.
86. Ortar, G.; Ligresti, A.; De Petrocellis, L.; Morera, E.; Di Marzo, V. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol., 2003, 65(9), 1473-1481.
87. Barann, M.; Molderings, G.; Bruss, M.; Bonisch, H.; Urban, B.W.; Gothert, M. Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br. J. Pharmacol., 2002, 137(5), 589-596.
88. Kaczocha, M.; Glaser, S.T.; Deutsch, D.G. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl. Acad. Sci. USA, 2009, 106(15), 6375-6380.
89. Deutsch, D.G.; Ueda, N.; Yamamoto, S. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukot. Essent. Fatty Acids, 2002, 66(2-3), 201-210.
90. Blankman, J.L.; Simon, G.M.; Cravatt B.F. A comprehensive profile of brain enzymes that hydrolise the endocannabinoid 2-arachidonoylglycerol. Chem. Biol., 2007, 14(12), 1347-1356.
91. Cravatt, B.F.; Demarest, K.; Patricelli, M.P.; Bracey, M.H.; Giang, D.K.; Martin, B.R.; Lichtman, A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA, 2001, 98(16), 9371-9376.
92. Chanda, P.; Gao, Y.; Mark, L.; Btesh, J.; Strassle, B.; Lu, P.; Piesla, M.; Zhang, M.Y.; Bingham, B.; Uveges, A.; Kowal, D.; Garbe, D.; Kouranova, E.; Ring, R.; Bates, B.; Pangalos, M.; Kennedy, J.; Whiteside, G.; Samad, T. Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system. Mol. Pharmacol., 2010, 78(6), 996-1003.
93. Schlosburg, J.E.; Blankman, J.L.; Long, J.Z.; Nomura, D.K.; Pan, B.; Kinsey, S.G.; Nguyen, P.T.; Ramesh, D.; Booker, L.; Burston, J.J.; Thomas, E.A.; Selley, D.E.; Sim-Selley, L.J.; Liu, Q.S.; Lichtman, A.H.; Cravatt, B.F. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat. Neurosci., 2010, 13(9), 1113-1119.
94. Marrs, W.R.; Blankman, J.L.; Horne, E.A.; Thomazeau, A.; Lin, Y.H.; Coy, J.; Bodor, A.L.; Muccioli, G.G.; Hu, S.S.; Woodruff, G.; Fung, S.; Lafourcade, M.; Alexander, J.P.; Long, J.Z.; Li, W.; Xu, C.; Möller, T.; Mackie, K.; Manzoni, O.J.; Cravatt, B.F.; Stella, N. The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat. Neurosci., 2010, 13(8), 951-957.
95. Walker, J.M.; Krey, J. F; Chu, C.J.; Huang, S.M. Endocannabinoids and related fatty acid derivatives in pain modulation. Chem. Phys. Lipids, 2002, 121(1-2), 159-172.
96. Lichtman, A.H.;Shelton, C.C.; Advani, T.; Cravatt, B.F. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptormediated phenotypic hypoalgesia. Pain, 2004, 109(3), 319-327.
97. Boger, D.L.; Sato, H.; Lerner, A.E.; Hedrick, M.P.; Fecik, R.A.; Miyauchi, H.; Wilkie, G.D.; Austin, B, J.; Patricelli, M.P.; Cravatt, B.F. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. Natl. Acad. Sci. USA, 2000, 97(10), 5044-5049.
98. Boger, D.L.; Miyauchi, H.; Du, W.; Hardouin, C.; Fecik, R.A.; Cheng, H.;Hwang, I.; Hedrick, M.P.; Leung, D.; Acevedo, O.; Guimarães, C.R.; Jorgensen, W.L.; Cravatt, B.F. Discovery of a potent, selective, and efficacious class of reversible alpha ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J. Med. Chem., 2005, 48(6), 1849-1856.
99. Consroe, P.; Musty, R.; Rein, J.; Tillery, W.; Pertwee, R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol., 1997, 38(1), 44-48.
100. Pertwee, R.G. Cannabinoids and multiple sclerosis. Mol. Neurobiol., 2007, 36(1), 45-59.
101. Barnes, M.P.; Kent, R.M.; Semlyen, J.K.; McMullen, K.M. Spasticity in multiple sclerosis. Neurorehabil. Neural Repair, 2003, 17(1), 66-70.
102. Paisley, S.; Beard, S.; Hunn, A.; Wight, J. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult. Scler., 2002, 8(4), 319-329.
103. Kita, M.; Goodkin, D.E. Drugs used to treat spasticity. Drugs, 2000, 59(3), 487-495.
104. Brown, P. Pathophysiology of spasticity. J. Neurol. Neurosurg. Psychiatry, 1994, 57(7), 773-777.
105. Adams, M.M.; Hicks, A.L. Spasticity after spinal cord injury. Spinal Cord, 2005, 43(10), 577-586.
106. Nielsen, J.B.; Crone, C.; Hultborn, H. The spinal pathophysiology of spasticity--from a basic science point of view. Acta Physiol., 2007, 189(2), 171-180.
107. Gilbert, S.L.; Zhang, L.; Forster, M.L.;Anderson, J.R.; Iwase, T.; Soliven, B.; Donahue, L.R.; Sweet, H.O.; Bronson, R.T.; Davisson, M.T.; Wollmann, R.L.; Lahn, B.T. Trak1 mutation disrupts GABA(A) receptor homeostasis in hypertonic mice. Nat. Genet., 2006, 38(2), 245-250.
108. Baker, D.; Pryce, G.; Croxford, J.L.;Brown, P.; Pertwee, R.G.; Huffman, J.W.; Layward, L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature, 2000, 404(6773), 84-87.
109. 2, cannabinoidreceptors. Br. J. Pharmacol., 2007, 150(4), 519-525.
110. Brady, C.M.; DasGupta, R.;Dalton, C.; Wiseman, O.J.;Berkley, K.J.; Fowler, C.J. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult. Scler., 2004, 10(4), 425-433.
111. Kavia, R.B.; De Ridder, D.; Constantinescu, C.S.; Stott, C.G.; Fowler, C.J. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler., 2010, 16(11), 1349-1359.
112. Freeman, R.M.; Adekanmi, O.; Waterfield, M.R.; Waterfield, A.E.; Wright, D.; Zajicek, J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int. Urogynecol. J. Pelvic Floor Dysfunct., 2006, 17(6), 636-641.
113. Killestein, J.; Hoogervorst, E.L.; Reif, M.; Kalkers, N.F.; Van Loenen, A.C.; Staats, P, G.; Gorter, R.W.; Uitdehaag, B.M.; Polman, C.H. (2002). Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology, 2002, 58(9), 1404-1407.
114. Zajicek, J.; Fox, P.; Sanders, H.; Wright, D.; Vickery, J.; Nunn, A.; Thompson A.; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebocontrolled trial. Lancet, 2003, 362(9395), 1517-1526.
115. Wade, D.T.; Makela, P.; Robson, P.; House, H.; Bateman, C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler., 2004, 10(4), 434-441.
116. Vaney, C.; Heinzel-Gutenbrunner, M.; Jobin, P.; Tschopp, F.; Gattlen, B.; Hagen, U.; Schnelle, M.; Reif, M. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult. Scler., 2004, 10(4), 417-424.
117. Zajicek, J.P.; Sanders, H.P.; Wright, D.E.; Vickery, P.J.; Ingram, W.M.; Reilly, S.M.; Nunn, A.J.; Teare, L.J.; Fox, P.J.; Thompson, A.J. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J. Neurol. Neurosurg. Psychiatry, 2005, 76(12), 1664-1669.
118. Wade, D.T.; Makela, P.M.; House, H.; Bateman, C.; Robson, P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler., 2006, 12(5), 639-645.
119. Collin, C.; Davies, P.; Mutiboko, I.K.; Ratcliffe, S. Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol., 2007, 14(3), 290-296.
120. Notcutt, W.; Langford, R.; Davies, P.; Ratcliffe S.; Potts, R. A placebo-controlled, parallel-group, randomised withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). Mult. Scler., 2012, 18(2), 219-228.
121. Novotna, A.; Mares, J.; Ratcliffe, S,; Novakova, I.; Vachova, M.; Zapletalova, O.; Gasperini, C.; Pozzilli, C.; Cefaro, L.; Comi, G.; Rossi, P.; Ambler, Z.; Stelmasiak, Z.; Erdmann, A.; Montalban, X.; Klimek, A.; Davies, P.; Sativex Spasticity Study Group. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol., 2011, 18(9), 1122-1131.
122. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet., 2003, 42(4), 327-360.
123. Anwar, K.;Barnes, M.P. A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis. NeuroRehabilitation, 2009, 24(4), 333-340.
124. Shakespeare, D.T.; Boggild, M.; Young, C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev., 2003, 4, CD001332.
125. Lorentzen, J.; Grey, M.J.; Geertsen, S.S.; Biering-Sørensen, F.; Brunton, K.; Gorassini, M.; Nielsen, J.B. Assessment of a portable device for the quantitative measurement of ankle joint stiffness in spastic individuals. Clin. Neurophysiol., 2011 [Epub ahead of print].
126. Agurell, S.; Halldin, M.; Lindgren, J.E.; Ohlsson, A.; Widman, M.; Gillespie, H.; Hollister, L. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev., 1986, 38(1), 21-43.
127. Baker, D.; Pryce, G.; Giovannoni, G.; Thompson A.J. The therapeutic potential of cannabis. Lancet Neurol., 2003, 2(5), 291-298.
128. Muller-Vahl, K.R.; Prevedel, H.; Theloe, K.; Kolbe, H.; Emrich, H.M.; Schneider, U. Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology, 2003, 28(2), 384-388.
129. Honarmand, K.; Tierney, M.C.; O'Connor, P.; Feinstein, A. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology, 2011, 76(13), 1153-1160.
130. Aragona, M.; Onesti, E.; Tomassini, V.; Conte, A.; Gupta, S.; Gilio, F.; Pantano, P.; Pozzilli, C.; Inghilleri, M. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin. Neuropharmacol., 2009, 32(1), 41-47.
131. Compston, A.; Coles, A. Multiple Sclerosis. Lancet, 2002, 359(9313), 1221-1231.
132. Bisogno.T.; Maurelli, S.; Melck, D.; De Petrocellis, L.; Di Marzo, V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem., 1997, 272(6), 3315-3323.
133. Klein, T.W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat. Rev. Immunol., 2005, 5(5), 400-411.
134. Yuan, M.; Kiertscher, S.M.;Cheng, Q.; Zoumalan, R.; Tashkin, D.P.; Roth, M.D. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J. Neuroimmunol., 2002, 133(1-2), 124-131.
135. Lyman, W.D.; Sonett, J.R.; Brosnan, C.F.; Elkin, R.; Bornstein, M.B. Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol., 1989, 23(1), 73-81.
136. Wirguin, I.; Mechoulam, R.; Breuer, A.; Schezen, E.; Weidenfeld, J.; Brenner, T. Suppression of autoimmune encephalomyelitis by cannabinoids. Immunopharmacology, 1994, 28(3), 209-214.
137. Pryce, G.; Ahmed, Z.; Hankey, D.J.; Jackson, S.J.; Croxford, J.L.; Pocock, J.M.; Ledent, C.; Petzold, A.; Thompson, A.J.; Giovannoni, G.; Cuzner, M.L.; Baker, D. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain, 2003, 126(10), 2191-2202.
138. 2 on autoreactive T Cells. Nat. Med., 2007, 13(4), 492-497.
139. Palazuelos, J.; Davoust, N.; Julien, B.; Hatterer, E.; Aguado, T.; Mechoulam, R.; Benito, C.; Romero, J.; Silva, A.; Guzmán, M.; Nataf, S.; Galve-Roperh, I. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J. Biol. Chem., 2008, 283(19), 13320-13329.
140. Croxford, J.L.; Miller, S.D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55, 212. J. Clin. Invest., 2003, 111(8), 1231-1240.
141. 2 receptor. Biochem. Pharmacol., 2006, 72(12), 1697-1706.
142. Arevalo-Martin, A.; Vela, J.M.; Molina-Holgado, E.;Borrell, J.; Guaza, C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci., 2003, 23(7), 2511-2516.
143. Lunn, C.A.; Fine, J.S.; Rojas-Triana, A.; Jackson, J.V.; Fan, X.; Kung, T.T.; Gonsiorek, W.; Schwarz, M.A.; Lavey, B.; Kozlowski, J.A.; Narula, S.K.; Lundell, D.J.; Hipkin, R.W.; Bober, L.A. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther., 2006, 316(2), 780-788.
144. Oka S.; Wakui, J.; Gokoh, M.; Kishimoto, S; Sugiura, T. Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol. Eur. J. Pharmacol., 2006, 538(1-3), 154-162.
145. Pertwee, R.G. Tolerance to the effect of delta1-tetrahydrocannabinol on corticosterone levels in mouse plasma produced by repeated administration of cannabis extract or delta1-tetrahydrocannabinol. Br. J. Pharmacol., 1974, 51(3), 391-397.
146. Bolton, C.; O'Neill, J.K.; Allen, S.J.; Baker, D. Regulation of chronic relapsing experimental allergic encephalomyelitis by endogenous and exogenous glucocorticoids. Int. Arch. Allergy Immunol., 1997, 114(1), 74-80.
147. Roth, M.D.; Baldwin, G.C.; Tashkin, D.P. Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. Chem. Phys. Lipids, 2002, 121(1-2), 229-239.
148. Pacifici, R.; Zuccaro, P.; Pichini, S.; Roset, P.N.; Poudevida, S.; Farre, M.; Segura, J.; De la Torre, R. Modulation of the immune system in cannabis users. JAMA, 2003, 289(15), 1929-1931.
149. Killestein, J.; Hoogervorst, E.L.; Reif, M.; Blauw, B.; Smits, M.; Uitdehaag, B.M.; Nagelkerken, L.; Polman, C.H. Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. J. Neuroimmunol., 2003, 137(1-2), 140-143.
150. Katona S.; Kaminski, E.; Sanders, H.; Zajicek, J. Cannabinoid influence on cytokine profile in multiple sclerosis. Clin. Exp. Immunol., 2005, 140(3), 580-585.
151. Bredt, B.M.; Higuera-Alhino, D.; Shade, S.B.; Hebert, S.J.; McCune, J.M.; Abrams, D.I. Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J. Clin. Pharmacol., 2002, 42(11 suppl), 82S-89S.
152. Webb, M.; Luo, L.; Ma, J.Y.; Tham, C.S. Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis. Neurosci. Lett., 2008, 439(1), 106-110.
153. Centonze, D.; Bari M.; Rossi, S.; Prosperetti, C.; Furlan, R.;Fezza F.; Chiara V.D.; Battistini, L.; Bernardi, G.; Bernardini, S.; Martino, G.; Maccarrone, M. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain, 2007, 130(Pt10), 2543-2553.
154. Di Filippo, M.; Pini, L.A.; Pelliccioli, G.P.; Calabresi, P.; Sarchielli, P. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in Multiple Sclerosis. J. Neurol. Neurosurg. Psychiatry, 2008, 79(11), 1224-1229.
155. Cabranes, A.; Venderova, K.; de Lago, E.; Fezza, F.; Sanchez, A.; Mestre, L.; Valenti, M.; Garcia-Merino, A.; Ramos, J.A.; Di Marzo, V.; Fernandez-Ruiz, J. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol. Dis., 2005, 20(2), 207-217.
156. Mestre, L.; Correa, F.; Arevalo-Martin, A.; Molina-Holgado, E.; Valenti, M.; Ortar, G.; Di Marzo, V.; Guaza, C. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem., 2005, 92(6), 1327-1339.
157. Malfitano, A.M.; Matarese, G.; Pisanti, S.; Grimaldi, C.; Laezza, C.; Bisogno, T.; Di Marzo, V.; Lechler, R.I.; Bifulco, M. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. J. Neuroimmunol., 2006, 171(1-2), 110-119.
158. Yiangou, Y.; Facer, P.; Durrenberger, P.; Chessell, I.P.; Naylor, A.; Bountra, C.; Banati, R.R.; Anand, P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol., 2006, 6, 12.
159. Benito, C.; Romero, J.P.; Tolon, R.M.; Clemente, D.; Docagne, F.; Hillard, C.J.; Guaza, C.;Romero, J. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci., 2007, 27(9), 2396-2402.
160. Sheng, W.S.; Hu, S.;Min, X.; Cabral, G.A.; Lokensgard, J, R.; Peterson, P.K. Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia, 2005, 49(2), 211-219.
161. Witting, A.; Chen, L.; Cudaback, E.; Straiker, A.; Walter, L.; Rickman, B.; Möller, T.; Brosnan C.; Stella, N. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc. Natl. Acad. Sci. USA, 2006, 103(16), 6362-6367.
162. Waksman, Y.; Olson, J.M.; Carlisle, S.J.; Cabral, G.A. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther., 1999, 288(3), 1357-1366.
163. Eljaschewitsch, E.; Witting, A.; Mawrin, C.; Lee, T.; Schmidt, P.M.; Wolf, S.; Hoertnagl, H.; Raine, C.S.; Schneider-Stock, R.; Nitsch, R.; Ullrich, O. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron, 2006, 49(1), 67-79.
164. Nagayama, T.; Sinor, A.D.; Simon, R.P.; Chen, J.; Graham, S.H.; Jin, K.; Greenberg, D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci., 1999, 19(8), 2987-2995.
165. Hampson, A.J.; Grimaldi, M.; Axelrod, J.; Wink, D. Cannabidiol and (-) Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA, 1998, 95(14), 8268-8273.
166. Abood, M.E.; Rizvi, G.; Sallapudi, N.; McAllister S.D. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity, Neurosci. Lett., 2001, 309(3), 197-201.
167. Shen, M.; Thayer, S.A. The cannabinoid agonist Win55, 212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. Brain Res., 1998, 783(1), 77-84.
168. Dutta, R.; Trapp, B.D. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology, 2007, 68(22 Suppl 3), S22-S31.
169. Hansen, H.H.; Schmid, P.C.; Bittigau, P.; Lastres-Becker, I.;Berrendero, F.; Manzanares, J.; Ikonomidou, C.; Schmid, H.H.; Fernandez-Ruiz, J.J.; Hansen, H.S. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem., 2001, 78(6), 1415-1427.
170. Hansen, H.H., Azcoitia, I., Pons, S., Romero, J., Garcia-Segura, L.M., Ramos, J.A., Hansen, H.S.; Fernandez-Ruiz, J. Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J. Neurochem., 2002, 82(1), 154-158.
171. Bilsland, L.G.; Dick, J.R.; Pryce, G.; Petrosino, S.; Di Marzo, V.; Baker, D.; Greensmith, L. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J., 2006, 20(7), 1003-1005.
172. Docagne, F.; Muneton, V.; Clemente, D.; Ali, C.; Loria, F.; Correa, F.; Hernangomez, M.; Mestre, L.; Vivien, D.; Guaza, C. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Mol. Cell Neurosci., 2007, 34(4), 551-561.
173. Dowie, M.J.; Howard, M.L.; Nicholson, L.F.; Faull, R.L.; Hannan, A.J.; Glass, M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice. Neuroscience, 2010, 170(1), 324-336.
174. Dowie, M.J.; Bradshaw, H.B.; Howard, M.L.; Nicholson, L.F.; Faull, R.L.; Hannan, A.J.; Glass, M. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease. Neuroscience, 2009, 163(1), 456-465.
175. Stover, J. F; Pleines, U. E; Morganti-Kossmann, M.C.; Kossmann, T.; Lowitzsch, K.; Kempski, O.S. Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur. J. Clin. Invest., 1997, 27(12), 1038-1043.
176. Sulkowski, G.; Dabrowska-Bouta, B.; Kwiatkowska-Patzer, B.; Struzyska, L. Alterations in glutamate transport and group I metabotropic glutamate receptors in the rat brain during acute phase of experimental autoimmune encephalomyelitis. Folia. Neuropathol., 2009, 47(4), 329-337.
177. Marte, A.; Cavallero, A.; Morando, S.; Uccelli, A.; Raiteri, M.; Fedele, E. Alterations of glutamate release in the spinal cord of mice with experimental autoimmune encephalomyelitis. J. Neurochem., 2010, 115(2), 343-352.
178. Pitt, D.; Werner, P.; Raine, C.S. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med., 2000, 6(1), 67-70.
179. Smith, T.; Groom, A.; Zhu, B; Turski, L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med., 2000 6(1), 62-66.
180. Hardin-Pouzet, H.; Krakowski, M.; Bourbonniere, L.; Didier-Bazes, M.; Tran, E.; Owens, T. Glutamate metabolism is downregulated in astrocytes during experimental allergic encephalomyelitis. Glia, 1997, 20(1), 79-85.
181. Ohgoh, M., Hanada, T.; Smith, T.; Hashimoto, T.; Ueno, M.; Yamanishi, Y.; Watanabe, M.; Nishizawa, Y. Altered expression of glutamate transporters in experimental autoimmune encephalomyelitis. J. Neuroimmunol., 2002, 125(1-2), 170-178.
182. Loría, F.; Petrosino, S.; Hernangómez, M.; Mestre, L.; Spagnolo, A.; Correa, F.; Di Marzo, V.; Docagne, F.; Guaza, C. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiol. Dis., 2010, 37(1), 166-176.
183. Siffrin, V.; Radbruch, H.; Glumm, R.; Niesner, R.; Paterka, M.; Herz, J.; Leuenberger, T.; Lehmann, S.M.; Luenstedt, S.; Rinnenthal, J.L.; Laube, G.; Luche; H., Lehnardt, S.; Fehling, H.J.; Griesbeck, O.; Zipp, F. In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity, 2010, 33(3), 424-436.
184. Black, J.A.; Dib-Hajj, S.; Baker, D.; Newcombe, J.; Cuzner, M.L.; Waxman, S.G. Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. Proc. Natl. Acad. Sci. USA, 2000, 97(21), 11598-11602.
185. Waxman, S.G. Acquired channelopathies in nerve injury and MS. Neurology, 2001, 56(12), 1621-1627.
186. Ahmed, Z.; Doward, A.I.; Pryce, G.; Taylor, D.L.; Pocock, J.M.; Leonard, J.P.; Baker, D.; Cuzner M.L. A role for caspase-1 and-3 in the pathology of experimental allergic encephalomyelitis: inflammation versus degeneration. Am. J. Pathol., 2002, 161(5), 1577-1586.
187. Pryce, G.; O'Neill, J.K.; Croxford, J.L.; Amor, S.; Hankey, D.J.; East, E.; Giovannoni, G.; Baker, D. Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J. Neuroimmunol., 2005, 165(1-2), 41-52.
188. Croxford, J. L; Pryce, G.; Jackson, S.J.; Ledent, C.; Giovannoni, G.; Pertwee, R.G.; Yamamura, T.; Baker, D. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J. Neuroimmunol., 2008, 193(1-2), 120-129.
189. Jackson, S.J.; Pryce, G.; Diemel, D.T.; Baker, D. Cannabinoid receptor null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience, 2005, 134(1), 261-268.
190. Zhang, H; Hilton, D. A; Hanemann, C. O; Zajicek, J. Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase Devidence for altered expression in multiple sclerosis. Brain Pathol., 2011, 21(5), 544-557.
191. Cabranes, A.; Pryce, G.; Baker, D.; Fernandez-Ruiz, J. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice. Brain Res., 2006, 1107(1), 199-205.
192. Marsicano, G.; Moosmann, B.; Hermann, H.; Lutz, B.; Behl, C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem., 2002, 80(3), 448-456.
193. Iuvone, T.; Esposito, G.; Esposito, R.; Santamaria, R.; Di Rosa, M.; Izzo, A.A. Neuroprotective effect of cannabidiol, a nonpsychoactive component from Cannabis sativa, on beta-amyloidinduced toxicity in PC12 cells. J. Neurochem., 2004, 89(1), 134-141.
194. Tagliaferro, P.; Javier Ramos, A.;Onaivi, E.S.; Evrard, S.G.; Lujilde, J.; Brusco, A. Neuronal cytoskeleton and synaptic densities are altered after a chronic treatment with the cannabinoid receptor agonist WIN 55, 212-2. Brain Res., 2006, 1085(1), 163-176.
195. Koch, G.; Mori, F.; Codecà, C.; Kusayanagi, H.; Monteleone, F.; Buttari, F.; Fiore, S.; Bernardi, G.; Centonze, D. Cannabis-based treatment induces polarity-reversing plasticity assessed by theta burst stimulation in humans. Brain Stimul., 2009, 2(4), 229-233.
196. Pahan, K.; Schmid, M. Activation of nuclear factor-kB in the spinal cord of experimental allergic encephalomyelitis. Neurosci. Lett., 2000, 287(1), 17-20.
197. Curran, N.M.; Griffin, B.D.; O'Toole, D.; Brady, K.J.; Fitzgerald, S.N.; Moynagh, P.N. The synthetic cannabinoid R(+)WIN 55, 212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. J. Biol. Chem., 2005, 280(43), 35797-35806.
198. Panikashvili, D.; Mechoulam, R.;Beni, S.M.; Alexandrovich, A.; Shohami, E. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J. Cereb. Blood Flow Metab., 2005, 25(4), 477-484.
199. Panikashvili, D.; Shein, N.A.; Mechoulam, R.; Trembovler, V.; Kohen, R.; Alexandrovich, A.; Shohami, E. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis., 2006, 22(2), 257-264.
200. Ramirez, B.G.; Blazquez, C.; Gomez del Pulgar, T.; Guzman, M.; de Ceballos, M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci., 2005, 25(8), 1904-1913.
201. Di Marzo, V.; Fontana, A.; Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J.C.; Piomelli, D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 1994, 372(6507), 686-691.
202. Panikashvili, D.; Simeonidou, C.; Ben-Shabat, S.; Hanus, L.; Breuer, A.; Mechoulam, R.; Shohami, E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature, 2001, 413(6855), 527-531.
203. van der Stelt, M.; Veldhuis, W.B.; van Haaften, G.W.; Fezza, F.; Bisogno, T.; Bar, P.R.; Veldink, G.A.; Vliegenthart, J.F.; Di Marzo, V.; Nicolay, K. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci., 2001, 21(2), 8765-8771.
204. Schäbitz, W.R.; Giuffrida, A.; Berger, C.; Aschof, A.; Schwaninger, M.; Schwab, S.; Piomelli, D. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke, 2002, 33, 2112-2114.
205. Karanian, D.A.; Brown, Q.B.; Makriyannis, A.;Bahr, B.A. Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus. Eur. J. Pharmacol., 2005, 508(1-3), 47-56.
206. Karanian, D.A.; Brown, Q.B.; Makriyannis, A.; Kosten, T.A.; Bahr, B.A. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J. Neurosci., 2005, 25(34), 7813-7820.
207. Galve-Roperh, I.; Aguado, T.; Rueda, D.; Velasco, G.; Guzman, M. Endocannabinoids: a new family of lipid mediators involved in the regulation of neural cell development. Curr. Pharm. Des., 2006, 12(18), 2319-2325.
208. Kim, S.H.; Won, S.J.; Mao, X.O.; Ledent, C.; Jin, K.; Greenberg, D.A. Role for neuronal nitric-oxide synthase in cannabinoid induced neurogenesis. J. Pharmacol. Exp. Ther., 2006, 319(1), 150-154.
209. Berghuis, P.; Rajnicek, A.M.; Morozov, Y.M.; Ross, R.A.; Mulder, J.; Urban, G.M.; Monory, K.; Marsicano, G.; Matteoli, M.;Canty, A.; Irving, A.J.; Katona, I.; Yanagawa, Y.; Rakic, P.; Lutz, B.; Mackie, K.; Harkany, T. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science, 2007, 316(5828), 1212-1216.
210. Aguado, T.; Romero, E.; Monory, K.; Palazuelos, J.; Sendtner, M.; Marsicano, G.; Lutz, B.; Guzman, M.; Galve-Roperh, I. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. J. Biol. Chem., 2007, 282(33), 23892-23898.
211. Galve-Roperh, I.; Aguado, T.; Palazuelos, J.; Guzman, M. The endocannabinoid system and neurogenesis in health and disease. Neuroscientist, 2007, 13(2), 109-114.
212. Molina-Holgado, F.; Rubio-Araiz, A.; Garcia-Ovejero, D.; Williams, R.J.; Moore, J.D.; Arevalo-Martin, A.; Gomez-Torres, O.; Molina-Holgado, E. CB2 cannabinoid receptors promote mouse neural stem cell proliferation. Eur. J. Neurosci., 2007, 2593, 629-634.
213. Rubio-Araiz, A.; Arevalo-Martin, A.; Gomez-Torres, O.; Navarro-Galve, B.; Garcia-Ovejero, D.; Suetterlin, P.; Sanchez-Heras, E.; Molina-Holgado, E.; Molina-Holgado, F. The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation. Mol. Cell Neurosci., 2008, 38(3), 374-380.
214. Jin, K.; Xie, L.; Kim, S.H.; Parmentier-Batteur, S.; Sun, Y.; Mao, X.O.; Childs, J.; Greenberg, D.A. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol. Pharmacol., 2004, 66(2), 204-208.
215. Gomez, O.; Sanchez-Rodriguez, A.; Le, M.; Sanchez-Caro, C.; Molina-Holgado, F.; Molina-Holgado, E. Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways. Br. J. Pharmacol., 2011, 163(7), 1520-1532.